secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193125-26-134501
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla initiates strategic review to monetize assets; Q4 net loss $9.8M, cash $7.1M
--------------------------------------------------------------------------------

- Board launched formal process to explore sale, licensing, or other strategic options; Tungsten Advisors engaged.
- Net loss Q4 2025: $9.8M versus $14.9M year ago; full year net loss $59.6M.
- Cash and equivalents $7.1M at Dec 31, 2025; company expects to extend runway via cost cuts and equity facility.
- March 2026 workforce reduction implemented; re-evaluating Phase 1 BA3182 enrollment and Phase 3 ozuriftamab vedotin timeline.
- Pre-paid advance agreements fully converted to common stock; no remaining obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000119312526134501/0001193125-26-134501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000119312526134501/bcab-20260331.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-134501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer